venBio Partners
Venture capitalSan Francisco · Seed–Late Stage · 11 people tracked
Also known as VENBIO PARTNERS LLC
Find your way into venBio Partners
2,873 people in our graph share verified history with the venBio Partners team — schools, employers, funds. One of them is your warm intro.
Investment thesis
venBio invests in life sciences companies developing novel therapeutics for unmet medical needs. The firm seeks teams building treatments with meaningful impact on patient care and works closely with them on development strategy, including intellectual property, chemistry and manufacturing (CMC), and clinical trial design and regulatory considerations. venBio is mindful of potential acquisition partners from the outset, positioning its companies to meet acquirer requirements. Its team's expertise and hands-on involvement aim to help companies make a larger impact and build lasting relationships with the leaders it backs.
Source: firm website, verified Sep 15, 2026.
Team · 11 people
from the firm's website & public directories
What they invest in
from 66 of 91 portfolio companiesBiotech ×60Healthtech ×39Medical Devices ×21Deep Tech ×9AI & Machine Learning ×8Digital Health ×7Advanced Manufacturing ×1Consumer ×1
HQs:United States×50Australia×1Canada×1United Kingdom×1Netherlands×1
Who they back
founder profiles across 24 portfolio companiesFounding team size:solo founder×132 founders×73 founders×24+ founders×2
Where their founders studiedfrom 15 founders with education data
The Johns Hopkins University School of Medicine ×4University of California, Berkeley ×3Harvard University ×2Massachusetts Institute of Technology ×2
What their founders studiedfrom 17 founders with field-of-study data
Life Sciences ×12Medicine ×4Engineering ×2Physics ×2
Where their founders worked beforefrom 16 founders with career history
Amgen ×3Boston Children's Hospital ×2Gladstone Institutes ×2OrbiMed ×2
Accelerator rootsportfolio companies that came through a program
Investments · 91 tracked
founders shown can be your intro pathBy year:2026 · 32025 · 12024 · 52023 · 32022 · 22021 · 82020 · 62019 · 32018 · 32017 · 42016 · 12015 · 748 dated
Harmony Biosciences develops innovative therapeutic treatments focused on rare neurological diseases.
BiotechHealthtechMedical DevicesNorthbrook, US
Jeffrey Aronin(Director)inJeffrey M. Dayno, M.D.(President and Chief Executive Officer)inPatrick Morris(Secretary and Treasurer)inRobert Repella(Director and Chief Executive Officer)Darien Parhad(Chief Financial Officer)
Board seatAaron Royston· per SEC Form D
Co-investorsAisling CapitalParagon Biosciences LLCValor Equity PartnersNovo HoldingsvenBio Global StrategicVivo Capital
Precision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
BiotechDeep TechHealthtechDurham, US
DEREK JANTZ(Executive Officer, Director)inMATTHEW KANE(Executive Officer, Director)Jeff Smith(Co-founder)inDerek Jantz(Co-founder)inTODD MELBY(Executive Officer)inMichael Amoroso(President, Chief Executive Officer)in
Board seatRobert Adelman· per SEC Form D
Co-investorsage1Agent CapitalAliment CapitalBrace PharmaF-Prime CapitalOCV Partners+4 more
Achieve Life Sciences is a late-stage specialty pharmaceutical company developing cytisinicline, a treatment for nicotine dependence and smoking cessation.
BiotechHealthtechVancouver, B.C., US
Anthony Clarke(Executive Officer)Richard Stewart(Director)Cindy Jacobs(Executive Officer, Director)inJaime Xinos(Executive Officer)inJohn Bencich(Executive Officer, Director)inAndrew D. Goldberg(Director, Chief Executive Officer and President)in
Co-investorsVivo CapitalFrazier Life Sciences
Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases.
AI & Machine LearningBiotechDigital HealthHealthtechLongevitySouth San Francisco, US
Martin Babler(President, Chief Executive Officer and Chairman of the Board)inMark Bradley(Chief Development Officer)inKolbot By(SVP, Head of Technical Operations)inJack Danilkowicz(Chief Commercial Officer)inJörn Drappa(Chief Medical Officer)inDavid M Goldstein(Chief Scientific Officer)in
Co-investorsForesite CapitalNextech InvestOrbiMedSamsara BioCapitalSR One Capital ManagementWestlake Village BioPartners+1 more
AstraZeneca develops and markets pharmaceutical products, vaccines, and biologics across oncology, cardiovascular disease, respiratory and immunology, and rare disease areas, serving patients and healthcare providers globally.
Cambridge, GB
Co-investors+ND Capital
ALX Oncology develops therapies for cancer treatment, operating in the biotechnology and medical technology sectors.
BiotechHealthtechMedical Devices
Corey Goodman(Chairman)inJason Lettmann(Chief Executive Officer)in
Co-investorsLightstone Venturesage1Foresite CapitalLogosVivo Capital
Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors.
BiotechHealthtechMedical DevicesCambridge, US
Elisabet de los Pinos, Ph.D.(Executive Officer, Director)Elisabet de los Pinos(Founder)inMichael Wyzga(Executive Officer)Dale Pfost, Ph.D.(Director)Alan E. Walts, Ph.D.(Director)Lewis Geffen(Executive Officer)
Co-investorsAdvent Life SciencesChiesi VenturesDroia VenturesForesite CapitalJazzya InvestmentsMedicxi+4 more
Compass Therapeutics uses proprietary antibody discovery platforms to generate and screen diverse panels of monoclonal and multispecific antibodies, aiming to identify synergistic therapeutic combinations.
BiotechHealthtechCambridge, US
Schuetz Thomas(Executive Officer, Director)inErrik Anderson(Executive Officer, Director)inThomas J. Schuetz(Executive Officer, Director)inVered Bisker-Leib(Executive Officer)inBarry Shin(Chief Financial Officer)inNeil Lerner(Senior Vice President, Chief Accounting Officer)in
Co-investorsBioBritF-Prime CapitalForesite CapitalOrbiMedVivo CapitalBorealis Ventures+1 more
Data I/O provides device programming systems and services for semiconductors including MCUs, UFS, eMMC, NAND flash, and security ICs, along with security provisioning like cryptographic key injection and device identity.
Advanced ManufacturingHardwareSemiconductors
William Wentworth(Chief Executive Officer, President, and Director)in
Immuron is an Australian biopharmaceutical company that develops and commercializes oral polyclonal antibodies derived from immunized bovine colostrum for treating infectious and inflammatory gastrointestinal diseases.
Johnson & Johnson develops prescription medicines and medical technology across areas including oncology, immunology, neuroscience, cardiopulmonary, cardiovascular, orthopaedics, surgery, and vision.
BiotechHealthtechMedical DevicesNew Brunswick, US
Edward Mead JohnsonJames Wood JohnsonRobert Wood Johnson IJoaquin DuatoinJ. Duato(Chief Executive Officer)
Co-investorsAisling CapitalAtlas VentureNaviMed CapitalPortland Seed FundSPRINGROCK VENTURESThe Column Group
Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.
AI & Machine LearningBiotechDeep TechMedical Devices
Mathai Mammen(CEO, President and Chairman)in
Co-investorsARCH Venture PartnersCatalio Capital Management, LPForesite CapitalFrazier Life SciencesGeneral CatalystNextech Invest+7 more
.png)
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule and antibody cancer therapies, including two FDA-approved medicines: revumenib (a menin inhibitor for acute leukemias) and axatilimab (a CSF-1R blocking antibody for graft-versus-host disease and fibrotic diseases), along with clinical-stage programs exploring expanded uses and combinations in oncology.
BiotechWaltham, US
John Pallies(Executive Officer)inArlene Morris(Executive Officer, Director)inMichael A. Metzger(Chief Executive Officer)inKeith A. Goldan(Chief Financial Officer)in
BoardDennis Podlesak(Director)inIvor Royston(Director)
Co-investorsForesite CapitalPappas CapitalSofinnova VenturesBlackRockDomain AssociatesMPM BioImpact
Tenaya Therapeutics is a biotechnology company focused on discovering and developing therapies for heart disease.
BiotechHealthtechSouth San Francisco, US
Deepak Srivastava, M.D.(Scientific Founder)inEric Olson, Ph.D.(Scientific Founder)Bruce R. Conklin, M.D.(Scientific Founder)inSheng Ding, Ph.D.(Scientific Founder)Saptarsi Haldar, M.D.(Scientific Founder)inEric Hyllengren(Chief Financial Officer)in
Co-investorsGV (Google Ventures)The Column Group
Axonis Therapeutics is a biotechnology company developing small-molecule medicines that target KCC2, a mediator of inhibition in the brain, to treat neurological disorders such as epilepsy and pain.
BiotechDeep TechBoston, US
Shane V. Hegarty(Chief Scientific Officer & Co-Founder)inJoanna Stanicka(Chief Executive Officer, President & Co-Founder)inJeff Imbaro(Chief Operating Officer)inTiasha Shafiq(Chief of Staff)in
BoardCorey . Goodman(Director)inJonathan Leff(Director)in
Co-investorsMRL Ventures FundSofinnova VenturesCivilization Ventures Management, LlcCreative Destruction Lab (CDL)Hatteras Venture PartnersIaso Ventures+7 more
Eyconis is a clinical-stage biotechnology company developing long-acting ophthalmic therapies for serious eye diseases such as wet age-related macular degeneration and diabetic macular edema using the TransCon technology platform.
BiotechDigital HealthMedical DevicesRedwood City, US
Emmett Cunningham(Executive Officer, Director)inMark Bachleda(Executive Officer, Director)inRobert Vitti(Executive Officer)inOliver Stauch(Executive Officer)inConrad Wang(Director)in
Co-investorsFrazier Life SciencesHealthQuest CapitalRA CapitalvenBio Global Strategic
NorthSea Therapeutics is a clinical-stage biopharmaceutical company developing oral fatty acid-derived therapies for liver and metabolic diseases, including intestinal failure-associated liver disease (IFALD), severe hypertriglyceridemia, and MASH.
BiotechDigital HealthHealthtech
Co-investorsNew Science VenturesYsios CapitalBGVNovo HoldingsSofinnova Ventures
Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing selective small molecule inhibitors to treat rare genetic and age-related diseases caused by dysregulated cellular metabolism.
BiotechBerkeley, US
Allison J. Hulme(CEO & President)inJohn Kincaid(Chief Scientific Officer)inDavis Ryman(Executive Officer)inMicah Zajic(Executive Officer)inIan Massey(Executive Officer)Stelios Tzannis(Executive Officer, Director)
Board seatRichard Gaster· per SEC Form D
Co-investorsCoastCapCTI Life Sciences Fund L.P.FJ LabsSofinnova VenturesApollo Health VenturesvenBio Global Strategic
Attralus develops pan-amyloid removal (PAR) therapeutics — biologics and imaging agents designed to bind and remove toxic amyloid — to treat patients with systemic amyloidosis across all disease types and stages.
BiotechHealthtechSouth San Francisco, US
Jonathan Wall(Executive Officer)inSpencer Guthrie(Executive Officer)Mark Timney(Executive Officer, Director)inBenson Fong(Executive Officer)Rahul Kakkar(Director)inGreg Bell(Executive Officer)
Board seatCorey Goodman· per SEC Form D
Co-investorsAlpha Wave GlobalBioBritJanus Henderson InvestorsREDMILESamsara BioCapitalvenBio Global Strategic+1 more
HealthtechSeattle, US
John D. Hoekman(Executive Officer, Director)in
BoardMichael Hite(Director)Stewart Parker(Director)
Board seatAaron Royston· per SEC Form D · $37.3M raise · filed Dec 2016
Co-investors5AM VenturesB Capital GroupvenBio Global StrategicWestlake Village BioPartners
.jpeg){kind=logo}
San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.
BiotechSan Diego, US
Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)
BoardKristina Burow(Director)inRichard Heyman(Director)inAmir Nashat(Director)in
Board seatRobert Adelman· per SEC Form D · $37.8M raise · filed Nov 2016
Co-investorsage1EcoR1 CapitalLAVLilly Asia VenturesNew Enterprise Associates (NEA)Vivo Capital+3 more
RayzeBio develops radiopharmaceutical therapies for cancer treatment.
BiotechHealthtechMedical DevicesSan Diego, US
Ken Song(Executive Officer, Director)inBen Hickey(President)inAbhi Bhat, PhD(Senior Vice President, Research & Development)Deborah Charych(Executive Officer)Yi Larson(Director)
Board seatAaron Royston· per SEC Form D
Co-investorsSamsara BioCapitalScion Life SciencesSofinnova VenturesTCG CrossoverVersant VenturesVivo Capital+1 more
BiotechSan Francisco, US
Curt Bradshaw(Executive Officer, Director, Promoter)inFrank Muhlenbeck(Mr. Muhlenbeck is a Manager of the Issuer.)
BoardCorey Goodman(Executive Officer, Director, Promoter)inSteven Dowdy(Director)George Rehm(Mr. Rehm is a member of the Board of Managers of the Issuer.)
Board seatRobert Adelman· per SEC Form D · $4M raise · filed Dec 2015
Tallac Therapeutics is a clinical-stage biopharmaceutical company developing oligonucleotide-based antibody conjugates (TRAAC candidates) designed to deliver immune-activating agents to tumor microenvironments for oncology indications.
BiotechHealthtechMedical DevicesBurlingame, US
Hong Wan(Executive Officer, Director)in
BoardRan Geng(Director)Michael Carusi(Director)Isaac Cheng(Director)Christine Brennan(Director)
Board seatJaume PonsCorey Goodman· per SEC Form D
Co-investorsLightstone VenturesMRL Ventures FundMatrix Partners ChinavenBio Global Strategic
35Pharma is a biopharmaceutical company developing biologics to treat diseases with high unmet medical need.
BiotechHealthtech
Ilia(CEO)Maureen(CSO)
Co-investorsFrazier Life SciencesJanus Henderson InvestorsVivo Capital
AI & Machine LearningBiotechDigital HealthHealthtech
Co-investorsDecheng CapitalSamsara BioCapitalKleiner Perkins
Akero develops engineered protein therapies for metabolic diseases, particularly MASH (metabolic dysfunction-associated steatohepatitis) and other conditions with high unmet medical need.
BiotechHealthtechMedical Devices
Co-investorsAtlas VentureForesite CapitalFrazier Life SciencesScion Life SciencesThe Innovation SpaceVersant Ventures
Alexion is a biopharmaceutical company focused on research and development of treatments for rare diseases, serving rare disease patients and their families worldwide.
BiotechHealthtechBoston, US
Co-investorsAndera PartnersConnecticut Innovations
Co-investorsAvoro Capital AdvisorsEpidarex CapitalF-Prime CapitalKeyhorse CapitalSofinnova VenturesSolasta Ventures
Arpeggio Bio develops pharmaceutical drugs that target transcription factors using artificial intelligence and RNA-sequencing technology, with lead programs in development for melanoma treatment and rare disease applications.
BiotechHealthtechBoulder, US
Joey Azofeifa(Founder)inLaura Norris(Executive Officer, Director)inTimothy Read(Executive Officer, Director)Eric Martin(Executive Officer)in
BoardAmit Mehta(Director)
Co-investorsFifty YearsFundersClubTau VenturesY CombinatorAlamo AngelsBoxOne Ventures+3 more
Arrakis Therapeutics develops RNA-targeted small-molecule (rSM) medicines, working independently and with partners to create drug candidates aimed at the root causes of disease.
AI & Machine LearningBiotechDeep TechHealthtechCambridge, US
Michael Gilman(Executive Officer, Director)inMark DeLong(CEO)inDavid Neafus(Executive Officer)inRussell C. Petter(Executive Officer)
BoardColleen Cuffaro(Director)inAlan E. Walts(Director)in
%20copy.jpg)
Co-investorsCanaan PartnersPfizer VenturesAdvent Life SciencesNextech InvestOUP (Osage University Partners)Pfizer Venture Investments+1 more
Artiva Bio is a clinical-stage biotechnology company developing NK cell-based therapies for autoimmune diseases, designed to be manufactured at scale and delivered in community settings.
BiotechHealthtechMedical DevicesSan Diego, US
Jennifer Bush(Executive Officer)inThomas J. Farrell(Executive Officer)Fred Aslan(Executive Officer, Director)inJason Litten(Executive Officer)inEsther van den Boom(Executive Officer)Peter Flynn(Executive Officer)in
Co-investors5AM VenturesEcoR1 CapitalRA CapitalvenBio Global Strategic
Attovia is a biotechnology company focused on drug development and clinical strategy, aiming to bring treatments to patients where none exist and create next-generation therapeutic options.
BiotechDigital Health
Zaneta Odrowaz(Founder)inTao Fu, MBA, M.S.(Founder, Chief Executive Officer, and President)Zaneta Odrowaz, Ph.D.(Chief Business Officer and Co-Founder)Petter Veiby(Chief Scientific Officer and Co-Founder)inHangjun Zhan, Ph.D.(Chief Technology Officer and Co-Founder)
Co-investorsEcoR1 CapitalFrazier Life SciencesIllumina VenturesNextech InvestSanofi VenturesVida Ventures+1 more
BiotechSan Francisco, US
Matthew Patterson(Executive Officer, Director)in
BoardJonathan Silverstein(Director)inSteve Squinto(Director)inKush Parmar(Director)inJonathan Leff(Director)Thomas Woiwode(Director)
Co-investorsAsset Management CompanyRA Capital5AM VenturesDeerfield Management CompanyOrbiMedVenrock
Aurinia is a biopharmaceutical company developing therapies for autoimmune diseases with significant unmet medical needs.
BiotechDigital HealthHealthtechMedical DevicesVictoria, US
Richard M. Glickman(Executive Officer, Director)inStephen W. Zaruby(Executive Officer, Director)Michael Martin(Executive Officer, Director)inDennis Bourgeault(Executive Officer)Mr. Tang(Chief Executive Officer and Chair of the Board)
BoardKurt von Emster(Director)in
Co-investorsLumira VenturesNew Enterprise Associates (NEA)
Axent Biosciences develops stem cell therapies to treat diseases like Parkinson's, using a proprietary cell cultivation platform to enable scalable and cost-effective manufacturing.
BiotechDeep TechHealthtechMedical DevicesNew MaterialsBerkeley, US
David Schaffer(Professor)
Caldera is a clinical-stage biotechnology company developing CLD-423, a bispecific antibody targeting the IL-23p19 and TL1A pathways for inflammatory bowel disease and other immunologic and inflammatory diseases.
BiotechHealthtech
Praveen Tipirneni(Chief Executive Officer)Liangsu Wang(Chief Scientific Officer)Zhong Liu(Chief Technology Officer)Aaron Pelta(Chief Business Officer)Colm White(Chief Program Officer)
Co-investorsAtlas VentureJanus Henderson InvestorsLAV
CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.
BiotechHealthtechSan Diego, US
Ken Song(Chairman, President and CEO)inKenneth Song, M.D.(Executive Officer, Director)Arvind Kush(Executive Officer)Timothy Lu, M.D.(Executive Officer)inBernie Huyghe, Ph.D.(Executive Officer)
BoardJeffrey Tong, Ph.D.(Director)
Co-investorsForesite CapitalOrbiMedSamsara BioCapitalTCG CrossoverThird Rock VenturesVida Ventures
Entact is a drug discovery company developing treatments for patients.
BiotechDeep TechWatertown, US
Victoria Richon(Executive Officer, Director, Promoter)inRuben Tommasi(Chief Scientific Officer)Michael Gutch(Chief Operating Officer)Alon Lazarus(Director)
BoardAndrew Sinclair(Director)Anna French(Director)in
Co-investorsAbingworthvenBio Global Strategic
Bristol Myers Squibb is a biopharmaceutical company that develops and delivers medicines across oncology, hematology, neuroscience, immunology, and cardiovascular disease areas.
BiotechHealthtechMedical DevicesNew York, US
Co-investorsKleiner PerkinsNew Enterprise Associates (NEA)Nextech InvestProspect Venture PartnersRho Capital PartnersRho Ventures+2 more
HistoWiz provides digital pathology services including precision histology, immunostaining, slide archiving, and AI-powered image analysis for research and clinical laboratories.
AI & Machine LearningBiotechHealthtechMedical DevicesNew York City, US
Ke Cheng(Founder/CEO)inLinh Hoang(Chief Executive Officer)inJerry Kuang(Chief Operations Officer)Julie Feldstein(Chief Pathologist)in
Co-investorsVivo CapitalY Combinator
Co-investorsDecheng CapitalForesite Capital
Impel Pharmaceuticals develops therapies for patients using its drug delivery technology and expertise with small and large molecules.
BiotechHealthtechMedical Devices
Co-investorsCowles VenturesNorwest Venture Partners
Insamo develops an automated platform for drug discovery that designs, synthesizes, and tests cyclic peptides at scale using machine learning and proprietary experimental data.
AI & Machine LearningBiotechDeep TechChippendale, AU
Tim Craven(CEO)inToby Passioura(CSO)inGlen McIntyre(COO)
BoardCOREY GOODMAN(Director)inMATT HERSHENSON(Director)in
Co-investorsBEVCCivilization Ventures Management, LlcMRL Ventures FundPlayground GlobalAxial VCvenBio Global Strategic
Lyell develops CAR T-cell therapies for cancer patients by leveraging deep expertise in T-cell biology and oncology.
BiotechDeep TechHealthtechMedical DevicesBothell, US
Stan Riddell(Executive Officer)Richard Klausner(Executive Officer, Director, Promoter)Stephen Hill(Executive Officer)inHeather Turner(Executive Officer)inRichard Goold(Executive Officer)inMargo Roberts(Executive Officer)
Co-investorsARCH Venture PartnersForesite Capital8VCAxial VC
Co-investorsAlpha Wave GlobalSofinnova Ventures
MindRhythm develops a portable, non-invasive medical device that uses the Headpulse algorithm and AI to triage stroke patients in the prehospital setting, helping paramedics identify Large Vessel Occlusion strokes and route patients to appropriate hospitals faster.
AI & Machine LearningDeep TechDigital HealthMedical Devices
John Keane(Co-Founder & CEO)inPaul Lovoi(Co-Founder & CTO)inWade Smith(Co-Founder & Chair of the Scientific Advisory Board)
Co-investorsDCVC (Data Collective)York IE
Neurogastrx is a biopharmaceutical company developing therapies for patients with gastrointestinal disorders.
BiotechHealthtechWoburn, US
Cyril De Colle(Founder)inCYRIL DE COLLE(Executive Officer, Director)inJAMES DETORE(Executive Officer)JAMES O'MARA(Executive Officer, Director)inPAUL ROGERS(Executive Officer)in
BoardDAVID ALLISON(Director)in
Co-investors5AM VenturesOrbiMedSamsara BioCapitalVivo CapitalRTW Investments L.P.venBio Global Strategic+1 more
NFlection is a biopharmaceutical company developing novel therapeutics.
BiotechMedical DevicesBoston, US
Christopher Powala(Chief Development Officer, Former President & CEO)Mark de Souza(Executive Officer, Director)in
BoardCorey Goodman(Director)Ketan Patel(Director)in
Co-investorsF-Prime CapitalvenBio Global Strategic
Oak Hill Bio develops therapies for patients with rare diseases, supported by experienced life science investors.
BiotechHealthtechMedical Devices
Pharvaris develops investigational oral therapies for people living with bradykinin-mediated angioedema.
BiotechHealthtech
Co-investorsBain Capital Life SciencesForesite CapitalKurma Partners
Portage is a clinical-stage immuno-oncology company developing novel cancer therapies with a portfolio in drug development.
BiotechHealthtechMedical Devices
Queenly is an online marketplace where users can buy and rent formal wear across iOS, Android, and web platforms.
ConsumerDirect to ConsumerE-commerceMarketplacesSan Francisco, US
Trisha Bantigue(Founder)inKathy Zhou-Patel(Founder)inMengzhou Zhou(Director)
Co-investorsAmino CapitalInterlace VenturesSHAKTIY CombinatorAndreessen HorowitzLocus Ventures+1 more
-2.png)
Regeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease.
BiotechHealthtechTarrytown, US
Co-investorsRidgeback CapitalSanderling VenturesWireframe Ventures
Teva Pharmaceuticals is a global pharmaceutical company that discovers, develops, and manufactures medicines to treat chronic conditions for patients across 57 markets.
BiotechHealthtechImpact & Social GoodMedical Devices
Co-investorsBlumberg Capital
San Diego, US
Mark S. Forman(Executive Officer)inMatthew Moore(Executive Officer)inJohn Nuss(Executive Officer)inJigar Choksey(Director)Martin Auster(Executive Officer)inChristopher W. Krueger(Executive Officer)
Co-investorsNew Science VenturesThird Point VenturesSilverArc PrivatevenBio Global Strategic
Verona Pharma develops treatments for chronic lung conditions.
BiotechHealthtechLondon
Jan-Anders Karlsson(Executive Officer, Director)inPeter Spargo(Executive Officer)inPatrick Humphrey(Director)Ken Cunningham(Director)Kenneth Newman(Executive Officer)Anders Ullman(Director)
Co-investorsAccess BiotechnologyAisling CapitalAndera PartnersForesite CapitalFrazier Life SciencesNew Enterprise Associates (NEA)+4 more
Cambridge, MA biotech developing single-course in vivo base editing medicines to permanently lower cardiovascular disease risk.
BiotechCambridge, US
Andrew Ashe(Executive Officer)Sekar Kathiresan(Executive Officer, Director)inAndrew Bellinger(Executive Officer)
BoardJohn Evans(Director)Anthony Philippakis(Director)inKrishna Yeshwant(Director)in
Co-investorsARCH Venture PartnersF-Prime CapitalGV (Google Ventures)RA CapitalCasdin CapitalForesite Capital
AI & Machine LearningBiotechHealthtech
Co-investorsAvoro Capital AdvisorsMedicxiTCG CrossoverUniQuest Extension Fund (UEF)
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
14ner OncologyAkero Therapeutics, Inc.Alexo TherapeuticsApellis PharmaceuticalsMarea Therapeutics, Inc.Menlo TherapeuticsTP TherapeuticsAbdera TherapeuticsAbderatxAblaze PharmaceuticalsAblazepharmaAkoustis TechnologiesAlimera SciencesArtur TherapeuticsAuspex PharmaceuticalsCaldera Therapeutics, Inc.Ceptur TherapeuticsCheckmate PharmaceuticalsCinncinatusFrequency TherapeuticsGood2Go, IncImmunomedicsINBRACEPhivida HoldingsRyvu TherapeuticsSelecta BiosciencesStargazer PharmaceuticalsSynthorxVentyx BiopharmaceuticalsVertoseViventia Biotech
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 22
16 IPOs · 6 acquisitions · showing 19Harmony BiosciencesNASDAQ: HRMYPrecision BioSciencesNASDAQ: DTILAchieve Life SciencesNASDAQ: ACHVAlumisNASDAQ: ALMSAlumniNYSE: AZNAlx OncologyNASDAQ: ALXOAura BiosciencesNASDAQ: AURACompass TherapeuticsNASDAQ: CMPXData I/ONASDAQ: DAIOImmuronNASDAQ: IMRNJohnson & JohnsonNYSE: JNJParabilis MedicinesNASDAQ: PBLSSyndax PharmaceuticalsNASDAQ: SNDXTenaya TherapeuticsNASDAQ: TNYAApellis Pharmaceuticalsacq. by BiogenAcelyrinacq. by AlumisCheckmate Pharmaceuticalsacq. by Regeneron PharmaceuticalsSynthorxacq. by SanofiVicebioacq. by Sanofi
Portfolio news
latest coverage across their companiesTeva · marketbeat.com · Aug 23, 2026
Aurinia Pharmaceuticals · finance.yahoo.com · Aug 20, 2026
Eyconis · biopharminternational.com · Aug 19, 2026
Alx Oncology · investing.com · Aug 18, 2026
Aura Biosciences · tickerreport.com · Aug 18, 2026
Tenaya Therapeutics · investing.com · Aug 18, 2026
Pharvaris · simplywall.st · Aug 17, 2026
Compass Therapeutics · simplywall.st · Aug 14, 2026
IPO stake values · per SEC filings
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Alx Oncology | 24.6% | $76.00 | Dec 2020 | $737.2M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has venBio Partners made?
- venBio Partners has 91 tracked investments, 22 of which have exited, including 5 dated in the last 24 months.
- What stage does venBio Partners invest at?
- venBio Partners invests at the Seed, Series A, Series B, Series C, Late Stage stages.
- What sectors does venBio Partners focus on?
- venBio Partners focuses on Biotech, Healthtech, Medical Devices.
- Where is venBio Partners located?
- venBio Partners is headquartered in San Francisco, US.
- Does venBio Partners lead rounds?
- venBio Partners typically participates in rounds rather than leading them.
- Who does venBio Partners co-invest with?
- venBio Partners most often shares deals with Foresite Capital, Vivo Capital, RA Capital, among 100 tracked co-investors.
Co-investors · 36
Foresite Capital is a healthcare-focused investment firm backing companies at the intersection of technology and biotechnology to personalize healthcare and accelerate medical innovation.
Vivo Capital is a global healthcare-focused investment firm operating a multi-strategy platform spanning venture capital, private equity, and public equity. It aims to expand healthcare access and drive innovation through its 'Ecosystem Strategy.'
Sofinnova is an investment firm focused on the life sciences and biotechnology sector, partnering with companies from inception through drug development, regulatory approval, company building, and IPO.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
RA Capital is a multi-stage investment firm focused on healthcare, life sciences, and planetary health, investing across public and private markets and creating new companies through its Raven incubation platform.
Samsara BioCapital is an investment firm backing the development of transformative therapeutics for patients, bringing together scientists, physicians, drug developers, and business leaders to support next-generation therapeutic breakthroughs.
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
Nextech Invest is a Zurich-based investment firm focused on emerging biotechnology companies, backing transformative cancer medicines and precision medicine advances worldwide.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
5AM Ventures is a life science venture capital firm founded in 2002 that invests primarily in private therapeutic companies, with a focus on biopharmaceuticals, drug delivery technologies, and life science instruments.
Westlake Village BioPartners is a Los Angeles-based life science venture capital firm that builds and incubates biotech companies around top entrepreneurs, providing hands-on support from ideation through clinical and commercial stages.
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
▶24 more co-investors
Kleiner PerkinsCanaan PartnersVersant VenturesThird Rock VenturesAbingworthLilly Asia VenturesGeneral CatalystVenrockPlayground GlobalOmega FundsApollo Health VenturesUberEclipse VenturesGeneral AtlanticHouseMorgenthalerAccess IndustriesCofounders CapitalSeroba Life Sciences4BIO CapitalRunway Growth CapitalKohFoundersMohr Davidow VenturesLuma Group
Firms observed investing alongside venBio Partners, from public investor directories. Shared companies are the overlap with venBio Partners's recorded portfolio.
Similar investors
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
EDBI is the investment platform of Singapore's Economic Development Board and Enterprise Singapore, focusing on high-growth technology companies expanding into Singapore and Asia.
Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.